financetom
Business
financetom
/
Business
/
Altice USA's Optimum Asks MSG Networks to Refund Over $125 Million to Customers
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Altice USA's Optimum Asks MSG Networks to Refund Over $125 Million to Customers
Jan 17, 2025 4:14 AM

06:45 AM EST, 01/17/2025 (MT Newswires) -- Altice USA ( ATUS ) subsidiary Optimum said Thursday that it has been negotiating with Sphere Entertainment ( SPHR ) unit MSG Networks for a solution to bring MSG content to fans and prevent non-viewers from having to pay for what they do not watch but the latter has refused all its offers.

The company said that MSG needs to take responsibility and issue refunds to subscribers for the programming they did not watch but were forced to pay for in 2024.

Optimum has therefore called on the programmer to refund customers over $125 million, representing the estimated $10 per month per subscriber that MSG Networks said its sports programming is worth.

In response to Optimum's statement, MSG asked for either the same deal it gave to YES Networks just a few months ago, its previous deal or to refund every subscriber $10 a month.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Form 8.3
Form 8.3
Mar 16, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Form 8.3
Form 8.3
Mar 16, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Monte Rosa Therapeutics Signs Supply Deal With Johnson & Johnson for Phase 2 Prostate Cancer Study
Monte Rosa Therapeutics Signs Supply Deal With Johnson & Johnson for Phase 2 Prostate Cancer Study
Mar 16, 2026
08:13 AM EDT, 03/16/2026 (MT Newswires) -- Monte Rosa Therapeutics ( GLUE ) said Monday it has entered a clinical supply agreement with Johnson & Johnson ( JNJ ) to evaluate investigational drug MRT-2359 in combination with Erleada in patients with metastatic castration-resistant prostate cancer with androgen receptor mutations. Under the agreement, Monte Rosa Therapeutics ( GLUE ) will sponsor...
CytomX Therapeutics Details Phase 1 Trial Results For Colorectal Cancer Treatment
CytomX Therapeutics Details Phase 1 Trial Results For Colorectal Cancer Treatment
Mar 16, 2026
08:12 AM EDT, 03/16/2026 (MT Newswires) -- CytomX Therapeutics ( CTMX ) said Monday a Phase 1 clinical trial evaluating varsetatug masetecan in patients with advanced colorectal cancer yielded confirmed response rates of up to 32%. Patients receiving the 10-milligram per kilogram dose demonstrated an estimated median progression-free survival of 7.1 months, the company said. The 8.6-milligram per kilogram cohort...
Copyright 2023-2026 - www.financetom.com All Rights Reserved